Empagliflozin in improving exercise tolerance in HFpEF: study protocol for an open-label, randomized controlled study
Abstract
Introduction: Heart failure with preserved ejection fraction (HFpEF) constitutes nearly half of patients with heart failure, but there is still a lack of treatment options to improve prognosis. Empagliflozin is a new hypoglycemic medication classified as sodium glucose cotransporter 2 inhibitors (SGLT2i); nonetheless, its effects on exercise tolerance in HFpEF remain ambiguous. Additional clinical studies are necessary to clarify the effect of SGLT2i in HFpEF. This study aims to evaluate the efficacy and safety of empagliflozin on exercise tolerance in patients with heart failure with preserved ejection fraction without diabetes, using cardiopulmonary exercise testing.
Methods and analysis: This study is a single-center, open-label, randomized controlled trial. We will randomly (1:1) assign 86 patients with an ejection fraction of more than 40% and class II-III heart failure to receive empagliflozin (10 mg once daily) or to maintain their original treatment regimen. The treatment duration will be 12 weeks. The primary endpoint is the evaluation of changes in peak oxygen uptake (peak VO2) after a 12-week period using cardiopulmonary exercise testing (CPET). The secondary endpoints encompassed additional parameters of CPET and echocardiography, N-terminal pro-B-type natriuretic peptide level, alanine aminotransferase level, aspartate transaminase level, estimated glomerular filtration rate level, New York Heart Association functional classification, and scores from the…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 86 participants or records.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.